Epicatechin breaks preformed glycated serum albumin and reverses the retinal accumulation of advanced glycation end products

European Journal of Pharmacology

Volumn 748, Issue , 2015, Pages 108-114

  Kim, Junghyun ^a   Kim, Chan Sik ^a   Moon, Min Kyong ^b,c   Kim, Jin Sook ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

Author keywords

Advanced glycation end products; Epicatechin; Glycation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; BOVINE SERUM ALBUMIN; EPICATECHIN; HUMAN SERUM ALBUMIN; SERUM ALBUMIN; CATECHIN; GLYCOSYLATED SERUM ALBUMIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACCUMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; NONHUMAN; RAT; RETINA BLOOD VESSEL; ANIMAL; BLOOD; BOVINE; CYTOLOGY; DRUG EFFECTS; METABOLISM; RETINA;

ADULT; ANIMALS; APOPTOSIS; CATECHIN; CATTLE; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; RATS; RETINA; RETINAL VESSELS; SERUM ALBUMIN;

EID: 84920749594     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.12.010     Document Type: Article

References (51)

1. S. Baba, N. Osakabe, M. Natsume, Y. Muto, T. Takizawa, and J. Terao In vivo comparison of the bioavailability of (+)-catechin, (-)-epicatechin and their mixture in orally administered rats J. Nutr. 131 2001 2885 2891
2. R. Babaei-Jadidi, N. Karachalias, N. Ahmed, S. Battah, and P.J. Thornalley Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine Diabetes 52 2003 2110 2120
3. X. Bai, Z. Wang, C. Huang, and L. Chi Investigation of non-enzymatic glycosylation of human serum albumin using ion trap-time of flight mass spectrometry Molecules 17 2012 8782 8794
4. M. Brownlee, H. Vlassara, A. Kooney, P. Ulrich, and A. Cerami Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking Science 232 1986 1629 1632
5. Y.A. Chen, and K.Y. Hsu Pharmacokinetics of (-)-epicatechin in rabbits Arch. Pharm. Res. 32 2009 149 154
6. G. Cheng, L.L. Wang, L. Long, H.Y. Liu, H. Cui, W.S. Qu, and S. Li Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats Br. J. Pharmacol. 152 2007 1196 1206
7. M.E. Cooper, V. Thallas, J. Forbes, E. Scalbert, S. Sastra, I. Darby, and T. Soulis The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation Diabetologia 43 2000 660 664
8. U. Denis, M. Lecomte, C. Paget, D. Ruggiero, N. Wiernsperger, and M. Lagarde Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction Free Radic. Biol. Med. 33 2002 236 247
9. L. Engelen, C.D. Stehouwer, and C.G. Schalkwijk Current therapeutic interventions in the glycation pathway: evidence from clinical studies Diabetes Obes. Metab. 15 2013 677 689
10. Z. Fu, J. Yuskavage, and D. Liu Dietary flavonol epicatechin prevents the onset of type 1 diabetes in nonobese diabetic mice J. Agric. Food Chem. 61 2013 4303 4309
11. M. Galleano, P.I. Oteiza, and C.G. Fraga Cocoa, chocolate, and cardiovascular disease J. Cardiovasc. Pharmacol. 54 2009 483 490
12. S.Y. Goh, and M.E. Cooper Clinical review: the role of advanced glycation end products in progression and complications of diabetes J. Clin. Endocrinol. Metab. 93 2008 1143 1152
13. D. Grassi, G. Desideri, S. Necozione, C. Lippi, R. Casale, G. Properzi, J.B. Blumberg, and C. Ferri Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate J. Nutr. 138 2008 1671 1676
14. Y. Guo, M. Lu, J. Qian, and Y.L. Cheng Alagebrium chloride protects the heart against oxidative stress in aging rats J. Gerontol. Ser. A Biol. Sci. Med. Sci. 64 2009 629 635
15. W.J. Hollands, D.J. Hart, J.R. Dainty, O. Hasselwander, K. Tiihonen, R. Wood, and P.A. Kroon Bioavailability of epicatechin and effects on nitric oxide metabolites of an apple flavanol-rich extract supplemented beverage compared to a whole apple puree: a randomized, placebo-controlled, crossover trial Mol. Nutr. Food Res. 57 2013 1209 1217
16. D.S. Jang, G.Y. Lee, Y.M. Lee, Y.S. Kim, H. Sun, D.H. Kim, and J.S. Kim Flavan-3-ols having a gamma-lactam from the roots of Actinidia arguta inhibit the formation of advanced glycation end products in vitro Chem. Pharm. Bull. 57 2009 397 400
17. S. Jew, S.S. AbuMweis, and P.J. Jones Evolution of the human diet: linking our ancestral diet to modern functional foods as a means of chronic disease prevention J. Med. Food 12 2009 925 934
18. Y. Kaji, S. Amano, T. Usui, T. Oshika, K. Yamashiro, S. Ishida, K. Suzuki, S. Tanaka, A.P. Adamis, R. Nagai, and S. Horiuchi Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells Investig. Ophthalmol. Vis. Sci. 44 2003 521 528
19. M. Kasper, C. Roehlecke, M. Witt, H. Fehrenbach, A. Hofer, T. Miyata, C. Weigert, R.H. Funk, and E.D. Schleicher Induction of apoptosis by glyoxal in human embryonic lung epithelial cell line L132 Am. J. Respir. Cell Mol. Biol. 23 2000 485 491
20. D.A. Kass, E.P. Shapiro, M. Kawaguchi, A.R. Capriotti, A. Scuteri, R.C. deGroof, and E.G. Lakatta Improved arterial compliance by a novel advanced glycation end-product crosslink breaker Circulation 104 2001 1464 1470
21. J. Kim, K.M. Kim, C.S. Kim, E. Sohn, Y.M. Lee, K. Jo, and J.S. Kim Puerarin inhibits the retinal pericyte apoptosis induced by advanced glycation end products in vitro and in vivo by inhibiting NADPH oxidase-related oxidative stress Free Radic. Biol. Med. 53 2012 357 365
22. H.S. Lee, S.H. Jung, B.S. Yun, and K.W. Lee Isolation of chebulic acid from Terminalia chebula Retz. and its antioxidant effect in isolated rat hepatocytes Arch. Toxicol. 81 2007 211 218
23. C. Manach, A. Scalbert, C. Morand, C. Remesy, and L. Jimenez Polyphenols: food sources and bioavailability Am. J. Clin. Nutr. 79 2004 727 747
24. M.A. Martin, E. Fernandez-Millan, S. Ramos, L. Bravo, and L. Goya Cocoa flavonoid epicatechin protects pancreatic beta cell viability and function against oxidative stress Mol. Nutr. Food Res. 58 2014 447 456
25. T. Mitsuhashi, H. Vlassara, H.W. Founds, and Y.M. Li Standardizing the immunological measurement of advanced glycation endproducts using normal human serum J. Immunol. Methods 207 1997 79 88
26. M. Mizutani, T.S. Kern, and M. Lorenzi Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy J. Clin. Investig. 97 1996 2883 2890
27. V.M. Monnier, and D.R. Sell Prevention and repair of protein damage by the Maillard reaction in vivo Rejuvenation Res. 9 2006 264 273
28. T. Ngawhirunpat, P. Opanasopi, M. Sukma, C. Sittisombut, A. Kat, and I. Adachi Antioxidant, free radical-scavenging activity and cytotoxicity of different solvent extracts and their phenolic constituents from the fruit hull of mangosteen (Garcinia mangostana) Pharm. Biol. 48 2010 55 62
29. M.K. Piskula, and J. Terao Accumulation of (-)-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues J. Nutr. 128 1998 1172 1178
30. S. Rahbar, K. Kumar Yernini, S. Scott, N. Gonzales, and I. Lalezari Novel inhibitors of advanced glycation endproducts Biochem. Biophys. Res. Commun. 262 1999 651 656
31. S. Rahbar, R. Natarajan, K. Yerneni, S. Scott, N. Gonzales, and J.L. Nadler Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation Clin. Chim. Acta 301 2000 65 77
32. G. Rimbach, M. Melchin, J. Moehring, and A.E. Wagner Polyphenols from cocoa and vascular health-a critical review Int. J. Mol. Sci. 10 2009 4290 4309
33. R. Rota, C. Chiavaroli, R.P. Garay, and P. Hannaert Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats Eur. J. Pharmacol. 495 2004 217 224
34. X. Shao, H. Chen, Y. Zhu, R. Sedighi, C.T. Ho, and S. Sang Essential structural requirements and additive effects for flavonoids to scavenge methylglyoxal J. Agric. Food Chem. 62 2014 3202 3210
35. S. Sugiyama, T. Miyata, Y. Ueda, H. Tanaka, K. Maeda, S. Kawashima, C. Van Ypersele de Strihou, and K. Kurokawa Plasma levels of pentosidine in diabetic patients: an advanced glycation end product J. Am. Soc. Nephrol. 9 1998 1681 1688
36. G. Suji, and S. Sivakami DNA damage by free radical production by aminoguanidine Ann. N. Y. Acad. Sci. 1067 2006 191 199
37. F.J. Tessier The Maillard reaction in the human body. The main discoveries and factors that affect glycation Pathol. Biol. 58 2010 214 219
38. M.C. Thomas, J.W. Baynes, S.R. Thorpe, and M.E. Cooper The role of AGEs and AGE inhibitors in diabetic cardiovascular disease Curr. Drug Targets 6 2005 453 474
39. P.J. Thornalley Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts Arch. Biochem. Biophys. 419 2003 31 40
40. R.G. Tilton, K. Chang, K.S. Hasan, S.R. Smith, J.M. Petrash, T.P. Misko, W.M. Moore, M.G. Currie, J.A. Corbett, and M.L. McDaniel Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation Diabetes 42 1993 221 232
41. F. Turgut, and W.K. Bolton Potential new therapeutic agents for diabetic kidney disease Am. J. Kidney Dis. 55 2010 928 940
42. S. Vasan, X. Zhang, A. Kapurniotu, J. Bernhagen, S. Teichberg, J. Basgen, D. Wagle, D. Shih, I. Terlecky, R. Bucala, A. Cerami, J. Egan, and P. Ulrich An agent cleaving glucose-derived protein crosslinks in vitro and in vivo Nature 382 1996 275 278
43. L. Wang, W. Tian, Z. Uwais, G. Li, H. Li, R. Guan, Z. Gao, and Z. Xin AGE-breaker ALT-711 plus insulin could restore erectile function in streptozocin-induced type 1 diabetic rats J. Sex. Med. 11 2014 1452 1462
44. A.M. Watson, A. Soro-Paavonen, K. Sheehy, J. Li, A.C. Calkin, A. Koitka, S.N. Rajan, D. Brasacchio, T.J. Allen, M.E. Cooper, M.C. Thomas, and K.J. Jandeleit-Dahm Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice Diabetologia 54 2011 681 689
45. B.H. Wolffenbuttel, C.M. Boulanger, F.R. Crijns, M.S. Huijberts, P. Poitevin, G.N. Swennen, S. Vasan, J.J. Egan, P. Ulrich, A. Cerami, and B.I. Levy Breakers of advanced glycation end products restore large artery properties in experimental diabetes Proc. Natl. Acad. Sci. USA 95 1998 4630 4634
46. S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, K. Koga, N. Sasaki, H. Yamamoto, M. Takeuchi, and Z. Makita Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes Biochem. Biophys. Res. Commun. 290 2002 973 978
47. S. Yamagishi, C.C. Hsu, M. Taniguchi, S. Harada, Y. Yamamoto, K. Ohsawa, K. Kobayashi, and H. Yamamoto Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy Biochem. Biophys. Res. Commun. 213 1995 681 687
48. S. Yamagishi, Y. Inagaki, S. Amano, T. Okamoto, M. Takeuchi, and Z. Makita Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties Biochem. Biophys. Res. Commun. 296 2002 877 882
49. S. Yamagishi, K. Nakamura, and T. Matsui Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy Curr. Drug Discov. Technol. 3 2006 83 88
50. S. Yamagishi, K. Nakamura, T. Matsui, Y. Inagaki, K. Takenaka, Y. Jinnouchi, Y. Yoshida, T. Matsuura, I. Narama, Y. Motomiya, M. Takeuchi, H. Inoue, A. Yoshimura, R. Bucala, and T. Imaizumi Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J. Biol. Chem. 281 2006 20213 20220
51. S. Yang, J.E. Litchfield, and J.W. Baynes AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats Arch. Biochem. Biophys. 412 2003 42 46